Mission Statement, Vision, & Core Values (2026) of Betta Pharmaceuticals Co., Ltd.

Founded in 2003 by returned PhD founders and headquartered in Hangzhou with R&D centers in Beijing and Hangzhou, Betta Pharmaceuticals Co., Ltd. (listed on the Shenzhen Stock Exchange as 300558.SZ on November 7, 2016) has built a full-capacity, modern high-tech pharmaceutical platform focused on oncology and innovative medicines; the company boasts a robust in-house pipeline with 2 programs granted NDA approval and 23 programs in various clinical stages, anchored by its flagship Icotinib Hydrochloride (Conmana®), China's first small-molecule EGFR-targeted anti-cancer drug approved by the NMPA in June 2011, while its mission to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases," vision to become a global leader in technical development and manufacturing of all‑natural performance materials, and core values of integrity, innovation, collaboration, quality and customer focus drive efforts to translate advanced science into more affordable, high‑quality therapies for patients at home and abroad.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Intro

• Founded: 2003 by a team of returned PhD holders
• Headquarters: Hangzhou, Zhejiang, China
• R&D Centers: Beijing and Hangzhou
• Stock listing: Shenzhen Stock Exchange, 7 November 2016 - 300558.SZ

Mission

• Develop and deliver innovative, affordable medicines that significantly improve patient outcomes-particularly in oncology.
• Translate cutting-edge scientific research into accessible therapies across China and global markets.
• Maintain vertically integrated capabilities from discovery through commercial manufacturing to ensure quality, supply security, and cost-effectiveness.

Vision

• Become a leading global biopharmaceutical innovator originating from China, driving breakthroughs in targeted cancer therapy.
• Build a sustainable R&D engine that advances multiple first-in-class and best-in-class candidates into global markets.
• Deliver long-term shareholder value by converting scientific assets into commercial successes while expanding international reach.

Core Values

• Scientific Rigor - evidence-driven drug discovery and development founded on rigorous clinical science and regulatory compliance.
• Patient Centricity - prioritizing meaningful clinical benefit and access for patients in need.
• Integrity & Quality - adherence to the highest standards across R&D, manufacturing, and commercialization.
• Collaboration - fostering cross-disciplinary teams internally and with external partners, leveraging academic and industrial expertise.
• Innovation & Persistence - continuous investment in novel mechanisms and perseverance through long development timelines.

• Icotinib (Conmana®) - China's first small-molecule EGFR-targeted anti-cancer drug (NMPA approved June 2011), representing Betta's capability to advance novel targeted therapies from lab to market.
• Pipeline scale - 2 NDA approvals and 23 clinical-stage programs demonstrate sustained R&D throughput and a diversified development portfolio across oncology indications.
• Integrated capabilities - in-house discovery, development, and manufacturing enable faster path-to-market and quality control for both innovative molecules and lifecycle management programs.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Overview

• Translating advanced science and technologies into innovative medicines to benefit patients in China and beyond.
• Prioritizing new drug development to achieve scientific innovation, create more affordable medicines and improve quality of life.
• Addressing unmet medical needs via continuous R&D investment and a full-capacity model spanning R&D, manufacturing and commercialization.
• Focusing on accessibility and affordability so innovation yields tangible patient benefit.

• Integrated value chain: discovery → clinical development → GMP manufacturing → marketing and distribution within China and selected export markets.
• Therapeutic focus: oncology, autoimmune disease, metabolic and cardiovascular areas with an expanding biologics portfolio.
• R&D-driven growth: combination of in-house discovery and partnerships/licensing for targeted pipelines and lifecycle optimization of key molecules.

• Pipeline breadth: multiple clinical-stage assets, including small molecules and biologics targeting oncology and immune-mediated diseases.
• Clinical activity: ongoing Phase II/III programs supported by domestic investigator sites and regulatory interactions with NMPA.
• Partnerships: strategic collaborations to accelerate IND filings and commercial scale-up for priority assets.

• Patient-centricity - measure decisions against patient benefit and access.
• Scientific rigor - invest in robust preclinical and clinical paradigms to de-risk development.
• Affordability & accessibility - prioritize pricing and supply strategies that widen patient access.
• Integrity & compliance - maintain GMP, GCP and regulatory standards across all sites.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Mission Statement

• Deliver high‑quality, all‑natural active ingredients and finished products that meet international safety and efficacy standards.
• Drive continuous technical innovation to adapt to evolving application needs across pharmaceutical, nutraceutical, and personal care markets.
• Operate with integrity-ensuring compliance, traceability, and ethical conduct across supply chains and manufacturing.
• Empower employees through training and qualification programs so that every product is backed by knowledgeable, accountable staff.

• Global leadership in all‑natural performance materials and ingredient technologies.
• Rapid adaptation to market trends and customer application requirements via agile R&D.
• Recognition by healthcare professionals and consumers for product safety, efficacy, and ethical practice.
• Sustainable growth that balances commercial performance with environmental and social responsibility.

• Quality First - uncompromising control from raw material sourcing through finished product release.
• Scientific Rigor - evidence‑based development and continuous investment in R&D capabilities.
• Integrity & Compliance - transparent governance, regulatory compliance, and ethical supply chain practices.
• Customer Centricity - co‑creating solutions with customers to meet real application needs.
• Employee Development - fostering expertise, accountability, and a culture of continuous improvement.

• Scale global footprint: expand export channels, regulatory registrations, and partnerships to increase international market share.
• Accelerate product innovation: focus on next‑generation natural excipients, stabilizers, and bioactive ingredients with documented performance advantages.
• Enhance quality systems: continuous upgrade of cGMP, digital traceability, and third‑party certifications to meet global regulatory expectations.
• Strengthen brand trust: targeted engagement with healthcare professionals and consumers to build recognition for safety and efficacy.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Vision Statement

• Integrity: unwavering compliance, transparent governance and ethical conduct across clinical development, regulatory affairs and commercialization.
• Innovation: heavy, sustained investment in R&D to advance novel therapeutics and biosimilars targeting unmet medical needs.
• Collaboration: strategic alliances with biotech firms, academic institutions and global partners to accelerate pipelines and broaden market access.
• Quality assurance: stringent GMP manufacturing, robust quality management systems and continuous improvement to ensure product safety and efficacy.
• Customer focus: patient- and clinician-centric engagement models, real‑world evidence generation and service initiatives to improve care delivery.

• Corporate governance: public reporting and board oversight aligned with Shenzhen Stock Exchange disclosure standards.
• Regulatory compliance: maintained GMP certifications across major sites and met post‑marketing surveillance requirements.

• Pipeline diversification: proprietary candidates, biosimilars and reformulations spanning oncology, cardiometabolic and CNS indications.
• R&D scale: 2023 R&D investment of ~RMB 520 million enabled multiple Phase I/II programs and expanded preclinical capabilities.
• Clinical activity: increased number of investigator‑initiated trials and registrational studies in China and select overseas jurisdictions.

• Strategic alliances: co‑development and licensing deals with biotech partners to share risk and accelerate time‑to‑market.
• External innovation: academic collaborations for target discovery and CRO partnerships to optimize trial execution and costs.

• GMP‑compliant facilities: multi‑site manufacturing footprint with capacity expansion projects aligned to commercial launches.
• Quality metrics: low recall rates, declining batch deviations year‑over‑year and investments in automated quality control systems.

• Patient centricity: patient support programs and adherence initiatives for chronic therapies.
• Physician outreach: medical affairs expansion to provide clinical education, real‑world data and guideline engagement.

• Reinvest a meaningful portion of profits into R&D (12.4% of revenue in 2023) to sustain innovative pipelines.
• Targeted M&A and licensing to complement internal capabilities and accelerate access to high‑value markets.
• Continuous modernization of manufacturing to meet global quality standards and support export growth.